Gilead Sciences | GILD - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.29B 73M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.27B 309M 2026-06
Gilead Sciences USD 1000M 445M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.96M 457K 2026-06
J&J USD 8B 67M 2026-06
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.02B 656M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
United Therapeutics USD 99.5M 33.9M 2026-06
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06